BIRC5 and breast carcinoma: Studies from 420 patients with long-term clinical follow-up showed that BIRC5 was found in 378 (90%) of the 420 primary breast cancer cases, and levels were substantially related to negative hormone receptor status (p = 0.0028) [24].